Discrepancy between antibiotics administered in acute exacerbations of chronic bronchitis and susceptibility of isolated pathogens in respiratory samples: multicentre study in the primary care setting

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 472-476

  Querol Ribelles, J M ^a   Molina, J ^b   Naberan, K ^b   Esteban, E ^c   Herreras, A ^c   Garcia de Lomas, J ^c,d  

^a HOSPITAL LLUÍS ALCANYÍS   (Spain)

^b GRAP   (Spain)

^c Instituto Valenciano de Microbiologia   (Spain)

^d Hospital Universitario de Valencia   (Spain)

Author keywords

Acute exacerbations of chronic bronchitis; Antimicrobial susceptibility; Telithromycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CONTROLLED STUDY; DILUTION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FEMALE; GENE; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BRONCHITIS, CHRONIC; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORAXELLA (BRANHAMELLA) CATARRHALIS; PREVALENCE; PRIMARY HEALTH CARE; SPAIN; SPUTUM; STREPTOCOCCUS PNEUMONIAE;

EID: 33750360462     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.05.034     Document Type: Article

References (22)

1. Murray C.J.L., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 349 (1997) 1498-1504
2. Mannino D.M. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121 5 Suppl. (2002) 121S-126S
3. Niederman M.S., McCombs J.S., Unger A.N., Kumar A., and Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 21 (1999) 576-591
4. Sheti S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117 Suppl. 2 (2000) 380S-385S
5. Pfaller M.A., Ehrhardt A.F., and Jones R.N. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am J Med 111 Suppl. 9A (2001) 4S-12S
6. Martinez F.J., and Anzueto A. Appropiate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med 118 Suppl. 7A (2005) 39S-44S
7. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45 (2001) 1721-1729
8. Baquero F., Garcia-Rodriguez J.A., Garcia-de-Lomas J., Aguilar L., and The Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 43 (1999) 357-359
9. Ho P.L., Que T.L., Tsang D.N., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 48 (2001) 659-665
10. Davidson R., Cavalcanti R., Brunton J.L., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 346 (2002) 747-750
11. Perez-Trallero E., Marimon J.M., Iglesias L., et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 9 (2003) 1159-1162
12. Doern G.V., and Brown S.D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 48 (2004) 56-65
13. Seppala H., Nissinen A., Yu Q., and Huovinen P. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 32 (1993) 885-889
14. Miravitlles M., Espinosa C., Fernandez-Laso E., et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116 (1999) 40-46
15. Doern G.V., Richter S.S., Miller N., et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 41 (2005) 139-148
16. Marco F., Bouza E., Garcia-de-Lomas J., Aguilar L., and Spanish Surveillance Group for Respiratory Pathogens. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. J Antimicrob Chemother 46 (2000) 557-564
17. Shortridge V.D., Doern G.V., Brueggemann J., Beyer J.M., and Flamm R.K. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 29 (1999) 1186-1188
18. Hyde T.B., Gay K., Stephens D.S., et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286 (2001) 1857-1862
19. Chen D.K., McGeer A., Azavedo J.C., and Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 341 (1999) 233-239
20. Ho P.L., Tse W.S., Tsang K.W., Kwok T.K., et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 32 (2001) 701-707
21. de la Campa A.G., Balsalobre L., Ardanuy C., Fenoll A., Perez-Trallero E., Liñares J., and Spanish Pneumococcal Infection Study Network G03/103. Fluoroquinolone resistance among penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis 10 (2004) 1751-1759
22. Perez-Trallero E., Marimón J.M., Iglesias L., and Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 9 (2003) 1159-1162